Receivers put Cellex subsidiary under review
This article was originally published in Clinica
Executive Summary
A receiver has been appointed by a French court to evaluate the prospects for LSL Biolafitte, Cellex Bioscience's French subsidiary, which may include its possible sale or liquidation. Shareholders face the loss of their total investment as the company's creditors may foreclose on its assets if Cellex does not get additional financing in the near future.